Publications by authors named "H Rik Endeman"
Background: Extubation failure is associated with an increased morbidity, emphasizing the need to identify factors to further optimize extubation practices. The role of biomarkers in the prediction of extubation failure is currently limited. The aim of this study was to investigate the prognostic value of cardiac (N-terminal pro-B-type natriuretic peptide (NT-proBNP), High-sensitivity Troponin T (Hs-TnT)) and inflammatory biomarkers (Interleukin-6 (IL-6) and Procalcitonin (PCT)) for extubation failure in patients with COVID-19 Acute Respiratory Distress Syndrome (C-ARDS).
View Article and Find Full Text PDFIntroduction: Severe COVID-19 is associated with reduced absolute lymphocyte counts, suggesting that lymphocyte subsets may serve as predictors of clinical outcomes in affected patients. Early identification of patients at risk for severe disease is crucial for optimizing care, accurately informing patients and their families, guiding therapeutic interventions, and improving patient flow in the ED. Given that immunosuppressive drugs significantly impact lymphocyte profiles, we aimed to determine the association between prior use of immunosuppressive drugs, lymphocyte subsets, and COVID-19 severity in our population with a high prevalence of immunosuppression.
View Article and Find Full Text PDFIntroduction: The goal of this study is to validate the accuracy of the 29-mRNA host response classifiers Inflammatix Bacterial-Viral-Non infected-3b (IMX-BVN-3b) and Severity-3b (IMX-SEV-3b) to identify bacterial and viral infections and to predict 30-day mortality in patients with suspected infections in the ED.
Methods: This prospective observational cohort study enrolled patients with suspected infections in a tertiary ED. IMX-BVN-3b was compared to clinically forced and consensus adjudicated bacterial/viral infection status and IMX-SEV-3b was compared to 30-day mortality.
Article Synopsis
- In critically ill patients, inflammation significantly impacts drug pharmacokinetics (PK), which may affect treatment effectiveness.
- Understanding the relationship between inflammatory biomarkers and PK parameters (absorption, distribution, metabolism, and excretion) can help optimize drug dosing in these patients.
- The review identified 31 relevant studies, highlighting that inflammation can alter drug absorption, distribution, metabolism, and excretion, with potential variations in effects depending on the specific drug and patient condition.
Article Synopsis
- A study was conducted to assess the effectiveness of higher doses of fluconazole in critically ill patients receiving Continuous Renal Replacement Therapy (CRRT), as there was limited clinical follow-up data on this practice.
- The research included patients on Continuous Veno-Venous Hemodialysis (CVVHD) and aimed to determine if target fluconazole levels were achieved with different dosing regimens.
- Results showed that a dosage of at least 400 mg twice daily was effective in reaching target levels for all patients, with this dose being the only significant factor affecting target attainment.